Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michelle Kwon

Optometrist Hartford, WI Doctor of Optometry

NPI 1447630744 CMS profile 1350093

1489 E Sumner St, Hartford, WI 53027

Open in the dashboard

General payments

$12,321

192 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Kwon of Hartford, WI is reported in the CMS Open Payments database as having received $12,321 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,936 23
2024 General $1,889 28
2023 General $2,078 34
2022 General $1,346 25
2021 General $1,241 24
2020 General $755 17
2019 General $3,076 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Kwon
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Michelle Kwon were reported at $1,936. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Michelle Kwon Optometrist median Middle half National median
2019 $3,076 $159 $67–$371 $163
2020 $755 $72 $29–$165 $114
2021 $1,241 $125 $46–$292 $132
2022 $1,346 $162 $66–$374 $149
2023 $2,078 $177 $72–$406 $160
2024 $1,889 $188 $77–$427 $164
2025 $1,936 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $3,558 52 payments
  2. Bausch & Lomb, a division of Bausch Health US, LLC $3,093 47 payments
  3. Johnson & Johnson Vision Care, Inc. $1,958 30 payments
  4. Alcon Vision LLC $1,223 25 payments
  5. CooperVision Inc. $683 13 payments
  6. Horizon Therapeutics plc $490 5 payments
  7. Allergan Inc. $217 4 payments
  8. Dompe US, Inc. $150 2 payments
  9. Tarsus Pharmaceuticals, Inc. $136 2 payments
  10. Amgen Inc. $125 1 payment
  11. Other $691 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,829 182 payments
  2. Travel and Lodging $1,386 9 payments
  3. Education $106 1 payment
Products named General payments · program years 2019–2025
  1. INFUSE $3,154 52 payments
  2. ULTRA $1,858 18 payments
  3. BIOTRUE $1,748 12 payments
  4. Acuvue $1,593 24 payments
  5. BIOTRUE ONE DAY $733 16 payments
  6. TEPEZZA $490 5 payments
  7. Clariti Contact Lens $448 7 payments
  8. DAILIES $374 10 payments
  9. ULTRA MULTIFOCAL TORIC $365 3 payments
  10. Precision 1 $315 5 payments
  11. Other $3,634 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$3,918

Medicare's payments for the services billed

Medicare patients

39

Average age 74

Services billed

41

18 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 38%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $136
$136 — —
Izervay
  • Astellas Pharma US Inc $88
$88 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record